Molecular design of prostaglandin probes in brain research:: High, specific binding to a novel prostacyclin receptor in the central nervous system

被引:39
|
作者
Suzuki, M [1 ]
Noyori, R
Långström, B
Watanabe, Y
机构
[1] Gifu Univ, Fac Engn, Dept Biomol Sci, Gifu 5011193, Japan
[2] Nagoya Univ, Dept Chem, Nagoya, Aichi 4648602, Japan
[3] Nagoya Univ, Res Ctr Mat Sci, Nagoya, Aichi 4648602, Japan
[4] Inst Chem, Dept Organ Chem, S-75185 Uppsala, Sweden
[5] Uppsala Univ, PET Ctr, S-75185 Uppsala, Sweden
[6] Osaka Biosci Inst, Dept Neurosci, Suita, Osaka 5650874, Japan
[7] Osaka City Univ, Sch Med, Dept Physiol, Osaka 5458585, Japan
关键词
D O I
10.1246/bcsj.73.1053
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Molecular design to develop a stable biochemical probe for a study of the role of prostacyclin (PGI(2)) in the brain led to the discovery of (15R)-16-m-tolyl-17, 18, 19,20-tetranorisocarbacylin (referred to as 15R-TIC), that selectively bind to a novel PGI(2) receptor, IP2, expressed in the central nervous system (CNS). This artificial prostaglandin with the 15R configuration exhibits high binding affinity for the IP2 receptor in the thalamus (IC50 = 32 nM) and weak affinity for the peripheral-type PGI(2) receptor, IP1, in the NTS (IC50 = 1.2 mu M). The length of the omega side-chain and the position of the methyl substituent on the aromatic ring strongly influence the binding characteristics. The features of the IP2 receptor were elucidated by quantitative mapping, specificity studies, and Scatchard analysis, as well as by a study using knockout mice with a tritium-labeled 15R-TIC and related radioligands. In order to conduct in vivo PET studies, a rapid methylation reaction using methyl iodide and an excess amount of an aryltributylstannane has been developed. This has successfully been applied to the synthesis of short-lived C-11-incorporated PET tracers, 15R-[C-11]TIC and its methyl eater. The PET experiments accomplished the imaging of the IP2 receptor in the brain of living rhesus monkeys through intravenous administration. The elimination of the C(15) chirality results in 15-deoxy-TIC with ten-fold higher affinity and selectivity for the IP2 receptor than original ISR-TIC. Neither 15R-TIC nor 15-deoxy-TIC inhibit platelets aggregation, up to 400 nM, while PGI(2) derivatives which bind with the IP1 receptor show a very potent inhibitory effect at a several nM level. Notably, these artificial CNS-specific PGI(2) ligands, like the unstable natural PGI(2) itself, prevent the apoptotic cell death of hippocampal neurons induced under high (50%) oxygen atmosphere and by xanthine and xanthine oxidase or serum deprivation. The difference in the binding potency between 15R-TIC and 15-deoxy-TIC for the IP2 receptor correlates well with the extent of the prevention of the neuronal cell death (IC50 values of 300 and 30 nM, respectively, under high oxygen atmosphere). 15R-TIC protects CA1 pyramidal neurons against ischemic damage in gerbils. Thus the designed TICs have neuronal survival-promoting activity both in vitro and in vivo, providing the possibility as a new type of chemotherapeutic agents for applications in neurodegeneration.
引用
收藏
页码:1053 / 1070
页数:18
相关论文
共 39 条
  • [31] Design and synthesis of novel central nervous system penetrant metabotropic glutamate receptor subtype 2 (mGlu2) negative allosteric modulators (NAMs) via scaffold hopping
    Childress, Elizabeth
    Wieting, Joshua
    Felts, Andrew
    Breiner, Megan
    Long, Madeline
    Luscombe, Vincent
    Rodriguez, Alice
    Cho, Hyekyung
    Blobaum, Anna
    Niswender, Colleen
    Conn, P.
    Lindsley, Craig
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
  • [32] MONOCLONAL IGMK IN A PATIENT WITH MOTOR NEURON DISEASE BINDS TO GM1, GD1B, AND TO HIGH MOLECULAR CENTRAL NERVOUS SYSTEM-SPECIFIC GLYCOCONJUGATES
    NOBILEORAZIO, E
    LEGNAME, G
    CARPO, M
    DAVERIO, R
    GALLANTI, A
    MOGGIO, M
    GIULIANI, A
    SONNINO, S
    SCARLATO, G
    ANNALS OF NEUROLOGY, 1989, 26 (01) : 174 - 174
  • [33] Acute Hypoxic Stress Induces Novel High Molecular Weight Corticotrophin Releasing Factor Receptor Type I (CRF-R1) Proteins in Central Nervous System Regions of Near Term Pregnant Rats.
    Lakshmanan, Jayaraman
    Richard, John D.
    Sugano, Sharon K.
    Ross, Michael G.
    REPRODUCTIVE SCIENCES, 2010, 17 (03) : 310A - 310A
  • [34] Design, Synthesis, Biological Evaluation, and Computational Studies of Novel Ureidopropanamides as Formyl Peptide Receptor 2 (FPR2)Agonists to Target the Resolution of Inflammation in Central Nervous System Disorders
    Mastromarino, Margherita
    Favia, Maria
    Schepetkin, Igor A.
    Kirpotina, Lylia N.
    Trojan, Ewa
    Niso, Mauro
    Carrieri, Antonio
    Leskiewicz, Monika
    Regulska, Magdalena
    Darida, Massimiliano
    Rossignolo, Francesco
    Fontana, Stefano
    Quinn, Mark T.
    Basta-Kaim, Agnieszka
    Leopoldo, Marcello
    Lacivita, Enza
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (06) : 5004 - 5028
  • [35] Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling
    Hirst, WD
    Abrahamsen, B
    Blaney, FE
    Calver, AR
    Aloj, L
    Price, GW
    Medhurst, AD
    MOLECULAR PHARMACOLOGY, 2003, 64 (06) : 1295 - 1308
  • [36] LOW NEUROTOXICITY OF LJC-10627, A NOVEL 1-BETA-METHYL CARBAPENEM ANTIBIOTIC - INHIBITION OF GAMMA-AMINOBUTYRIC ACID(A), BENZODIAZEPINE, AND GLYCINE RECEPTOR-BINDING IN RELATION TO LACK OF CENTRAL-NERVOUS-SYSTEM TOXICITY IN RATS
    HIKIDA, M
    MASUKAWA, Y
    NISHIKI, K
    INOMATA, N
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (02) : 199 - 202
  • [37] MUSCARINIC RECEPTOR HETEROGENEITY IN RAT CENTRAL-NERVOUS-SYSTEM .2. BRAIN RECEPTORS LABELED BY [H-3] OXOTREMORINE-M CORRESPOND TO HETEROGENEOUS M2 RECEPTORS WITH VERY HIGH-AFFINITY FOR AGONISTS
    GILLARD, M
    WAELBROECK, M
    CHRISTOPHE, J
    MOLECULAR PHARMACOLOGY, 1987, 32 (01) : 100 - 108
  • [39] ANTIDIARRHEAL AND CENTRAL NERVOUS-SYSTEM ACTIVITIES OF SC-27166 (2-[3-5-METHYL-1,3,4-OXADIAZOL-2-YL)-3,3-DIPHENYLPROPYL]-2-AZABICYCLO[2.2.2]OCTANE) - NEW ANTIDIARRHEAL AGENT, RESULTING FROM BINDING TO OPIATE RECEPTOR-SITES OF BRAIN AND MYENTERIC PLEXUS
    MACKERER, CR
    BROUGHAM, LR
    EAST, PF
    BLOSS, JL
    DAJANI, EZ
    CLAY, GA
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1977, 203 (03): : 527 - 538